Oxymorphone HCl (Opana) for the Relief: Hale et al.

Posted by James

A multicenter, randomized, double-blind, placebo-controlled, active-controlled trial was conducted to compare the analgesic efficacy and safety of oxymorphone ER with placebo and oxycodone controlled release (CR) in ambulatory patients with moderate-to-severe chronic low back pain who required opioid therapy. Patients received oxymorphone ER 10 to 110 mg or oxycodone CR 20 to 220 mg every 12 hours during a seven-day to 14-day dose-titration phase.

Patients who achieved analgesia at a stable opioid dose entered an 18-day double-blind treatment phase. These patients either continued opioid therapy or received placebo.
canadian antibiotics

The use of rescue medication was permitted with oral morphine sulfate 15 mg every four to six hours on an unlimited basis for the first four days to minimize the risk of opioid-withdrawal symptoms in the patients who received placebo. After the first four days, rescue medication was limited to a total of 30 mg/day. No other analgesics—opioid or non-opioid—were permitted during the study.

Because of the titration phase, all of the patients had achieved analgesia at the beginning of the treatment phase. The mean change in pain intensity from baseline to endpoint was significantly greater with the use of placebo than with oxymorphone ER or oxycodone CR. This indicated that the placebo patients, after being stabilized with an opioid in the titra-tion phase, experienced a large increase in pain intensity, compared with patients who continued with opioid therapy.

Patients who continued with either oxymorphone or oxycodone experienced comparable changes in pain intensity. Pain ratings were significantly lower for patients receiving oxymorphone ER than for those receiving placebo (P = 0.0001).

ADEs were similar for oxymorphone ER and oxycodone CR; the most frequent ADEs were constipation and sedation. Both drugs were generally safe and effective for controlling low back pain.
eriacta tablets

Both oxymorphone ER and oxycodone CR provided significant analgesia with comparable ADE profiles. Oxymorphone ER was equianalgesic to oxycodone CR at almost half the milligram dose. Oxy-morphone ER offered superior analgesic efficacy compared with placebo.

Fifty-seven percent of patients who received placebo dropped out of the trial because of lack of efficacy, compared with 16% to 20% of those who were treated with an opioid.

McIlwain et al.

A 52-week, multicenter, open-label extension study was performed at 32 centers in the U.S. to evaluate the safety, tolerability, and effectiveness of oxymor-phone ER in 153 patients with moderate-to-severe chronic osteoarthritis-related pain. Patients were eligible for this trial only after completing a previous randomized, double-blind, placebo-controlled and active-controlled trial.

The study population for the newer trial included opioid-naive patients from the placebo arm of the original trial. Most patients received an initial dose of 20 mg every 12 hours, but an alternative initial dose was permitted at the discretion of the investigator.

Patients who had received oxymor-phone ER or oxycodone CR in the original trial continued at the same milligram dose with oxymorphone ER.

Throughout this study, oxymorphone ER was found to be safe and effective for the relief of moderate-to-severe chronic osteoarthritis-related pain. Patients remained stable, at mild levels of pain intensity, with regular dosing every 12 hours. cheap antibiotics

More than 80% of the patients rated their overall satisfaction with oxymor-phone ER as “excellent,” “very good,” or “good.” Only a small number of patients (7%-8%) withdrew as a result of insufficient therapeutic efficacy.

Opioid rescue medication was not permitted, yet few patients withdrew because of insufficient therapeutic effect. This suggests that oxymorphone ER provided complete 12-hour analgesia for chronic pain on a long-term basis.

Katz et al.

A 12-week, randomized, placebo-controlled study was conducted to determine the efficacy and tolerability of oxymorphone ER in opioid-naive patients with moderate-to-severe chronic low back pain. The study included patients 18 years of age and older. Doses were titrated with oxymorphone ER in 5- to 10-mg increments every 12 hours, every three to seven days, until a well-tolerated, stabilized dose was reached. In 63% of the patients, the dose was stabilized, usually within a one-month time period. Patients were then assigned to continue their oxymorphone ER dose or to receive placebo every 12 hours for 12 weeks.

Oxymorphone IR was also available every four to six hours, as needed, for the first four days and twice daily for the remainder of the study.

After randomization, 68% of the oxy-morphone ER and 47% of the placebo patients completed 12 weeks of double-blind treatment. Pain intensity increased significantly more in the placebo group of patients than in the oxymorphone ER group (P < 0.0001).

Oxymorphone ER was well tolerated without unexpected ADEs. During titra-tion, 18% discontinued because of ADEs and 1% as a result of a lack of efficacy. After randomization, approximately 8% of patients in each group discontinued therapy because of ADEs. Placebo patients discontinued treatment sooner as a result of a lack of efficacy than those receiving oxymorphone ER (P< 0.0001).

Opioid withdrawal was limited to two patients in the placebo group and one in the oxymorphone ER group. Therefore, stabilized doses of oxymorphone ER were generally safe and effective over a 12-week, double-blind treatment period for these patients. erectalis 20

Hale et al.

Another 12-week, randomized, double-blind, placebo-controlled trial demonstrated the efficacy and safety of oxy-morphone ER for opioid-experienced patients with chronic, moderate-to-severe low back pain. Patients had to be at least 18 years of age and had to be currently receiving a stable, around-the-clock opioid pain medication equivalent to at least 60 mg/day of oral morphine.

This study consisted of two stages in order to assess efficacy in long-term pain relief. All patients were switched to an almost equianalgesic dose of oxymor-phone ER and were entered into an open-label titration period. After they were stabilized with a twice-daily dose that provided adequate pain relief and tolera-bility, they were entered into a 12-week, double-blind, placebo-controlled treatment period. Stabilized patients (n = 143) either continued with their fixed dose of oxymorphone ER or received placebo. Oxymorphone 5-mg tablets were available as needed for withdrawal symptoms.

The primary efficacy endpoint was the change in average pain intensity from the baseline evaluation to the final study visit.

Pain intensity increased significantly with placebo, whereas oxymorphone ER maintained effective analgesia throughout the entire 12 weeks at the same stabilized dose. Placebo patients were approximately eight-fold more likely than treated patients to stop treatment because of a lack of efficacy (P < 0.001). The most frequently reported adverse events were nausea, constipation, headache, and somnolence.

Oxymorphone ER provided efficacious, long-term analgesia and was well tolerated for these patients.